RespireRx Pharmaceuticals Inc (fka RSPI)

[LTListener]

Agree with you. The due diligence is out there on this one in the filings and more if an investor takes the time to read.

Not only do they value the OSA program at 20+ milllion. The AMPAkine program sold for 10 million + milestones over a decade ago. They re-acquired those assets and apparently ironed out some issues with past trials that was holding things up. Now this platform is obviously moving with all the recent publication efforts and the DOD funded phase 2 for SCI. It is logical speculation that success in this phase 2 will parlay into much more for the platform including ADHD.

Then KRM-ll-81 with a superior preclinical profile now seeking grant funding might just be the most valuable of them all as a candidate for both pain and epilepsy indications!

This pipeline has been so undervalued it was a headscratcher when conducting due diligence. Explains why all these stakeholders have lined up behind owning equity positions as well as preferred shares and such.